close

Enter

Log in using OpenID

Pulmonary Arterial Hypertension (PAH) Market

embed
Pulmonary hypertension or PH is a condition in which the blood pressure rises in the pulmonary artery, vein, or capillaries
Pulmonary Arterial Hypertension (PAH) Market
Current Industry Status, Target Audience,Top
Key Players
Pulmonary hypertension or PH is a condition in which the blood pressure rises in the
pulmonary artery, vein, or capillaries (collectively known as lung vasculature), which might
lead to shortness of breath, fainting, leg swelling, and dizziness, among others. Pulmonary
hypertension may be a relentless disease with a noticeable reduction in exercise tolerance.
Pulmonary arterial hypertension or PAH indicates that the patient has high blood pressure in
arteries that carry blood from the heart to the lungs. With PAH, the arteries in the lungs
become thin or get blocked resulting into irregular blood flow. Since the flow of blood is
hindered, it becomes hard for the blood to flow evenly thereby, increasing the blood pressure
in the patient. In layman terms, it means that the heart works harder to pump blood. It may
lead to weakening of the heart muscles after a certain period of time. Ultimately, pulmonary
arterial hypertension may cause heart failure.
For In depth Information Get Sample Copy of this Report @
https://www.coherentmarketinsights.com/insight/request-sample/203
Based on the reports gathered from a variety of sources, including CDC (Centers for Disease
Control and Prevention) and WHO (World Health Organization), the global prevalence of
pulmonary arterial hypertension is projected to be 100,000 – 200,000, that is about 15 - 50
patients per million of the population. Even though, the treatment available for pulmonary
arterial hypertension is rather limited, various treatment options are available to decrease
symptoms, slow down disease progression, and improve the quality of life. Endothelin receptor
antagonists or ERAs, phosphodiesterase-5 (PDE-5) inhibitors and Prostacyclin and prostacyclin
analogs are some of the widely prescribed drug classes used for treatment of the disease.
Lately, a new drug class known as the soluble guanylate cyclase or sGC stimulators has been
recognized to be effective in treating people with PAH.
On the contrary, the expiry of patents of major pulmonary arterial hypertension drugs such as
Letairis, Tracleer, Tyvaso, and Adcirca is projected to pose a challenge for the growth of the
market, as the generic versions of these drugs will be sold at 70% to 80% lower prices than
that of the present branded drugs. Various breakthrough therapies for treatment of pulmonary
arterial hypertension is projected to be a growth factor for the PAH treatment drug
manufacturers, since the available drugs for the same are not sufficient to meet the patient’s
needs. These factors will fuel growth of the PAH market and increase the demand for PAH
treatment drugs.
Report includes chapters which deeply display the following deliverable about industry :
• Pulmonary Arterial Hypertension (PAH) Market Research Objective and Assumption
• Pulmonary Arterial Hypertension (PAH) Market Purview - Report Description, Executive
Summary, and Coherent Opportunity Map (COM)
• Pulmonary Arterial Hypertension (PAH) Market Dynamics, Regulations, and Trends Analysis Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Pulmonary Arterial Hypertension (PAH) Market, By Regions
• Pulmonary Arterial Hypertension (PAH) Market Competition by Manufacturers including
Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and
Product Type.
• Pulmonary Arterial Hypertension (PAH) Market Manufacturers Profiles/Analysis including
Company Basic Information, Manufacturing Base and Its Competitors.
• Pulmonary Arterial Hypertension (PAH) Market Manufacturing Cost Analysis including Key
Raw Materials and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Pulmonary Arterial Hypertension (PAH) Market Forecast including Production, Consumption,
Import and Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Pulmonary Arterial Hypertension (PAH) Market Taxonomy
On the basis of drug class, the global pulmonary arterial hypertension market is classified into:
ERA
Prostacyclin and Prostacyclin Analogs
sGC Stimulators
PDE-5 Dipsticks
On the basis of application, the global pulmonary arterial hypertension market is classified into:
Hospitals
Clinics
Others
ERAs was the largest segment in the current scenario. However, the prostacyclin and
prostacyclin analogs segment is projected to expand at the highest CAGR over the forecast
period, owing to the authorization of Orenitram (treprostinil extended release tablet) in 2013
and the anticipated endorsement of Uptravi (selexipag) in 2016.
Growing prevalence of cardiac diseases to drive growth of the overall pulmonary arterial
hypertension (PAH) market
Owing to the sedentary lifestyles, growing consumption of fast food, and lack of exercise, the
global numbers for the patients with cardiac diseases is expected to rise substantially over the
forecast period thereby, increasing the susceptibility of pulmonary arterial hypertension among
the global population. This would propel the overall growth of the PAH market in the near
future.
North America accounted for the largest market share of the global PAH treatment market,
followed by Europe. These regional market are projected to witness considerable growth in the
forecast period, owing to the freshly approved PAH medicines in the market and high
prevalence of heart diseases.
Browse Complete Report For More Information @
https://www.coherentmarketinsights.com/ongoing-insight/pulmonary-arterial-hypertension-pahmarket-203
Some of the major companies operating in the pulmonary arterial hypertension (PAH) market in
the current scenario are Actelion Pharmaceuticals, Ltd., Gilead Sciences, Inc., United
Therapeutics Corporation, Bayer HealthCare, Pfizer, Inc., Novartis International AG and
GlaxoSmithKline plc.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Author
Alex Huge
Alex Huge201   document Email
Document
Category
Health and Medicine
Views
6
File Size
123 KB
Tags
Pulmonary Arterial Hypertension (PAH) Market, market
1/--pages
Report inappropriate content